Pfizer Inc (PFE) 29.37 $PFE
Market Maker Surveillance Report. PFE, TWX, CSCO, MDT, DEPO, QQQ, Bearishly Biased Price Friction For Thursday, September 4th 2014
M2 - 2 hrs 17 mins ago
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4751 companies with "abnormal" market making, 1909 companies with positive Friction Factors and 3133 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bearish bias) in their stock prices. This means that there was more buying than selling in the stocks and their stock prices dropped. Pfizer Inc (NYSE
FE), TIME WARNER INC. (NYSE:TWX), CISCO SYSTEMS INCORPORATED (NASDAQ:CSCO), Medtronic Inc (NYSE:MDT), Depomed Inc (NASDAQ
EPO), Powershares Qqq Trust Series 1 (NASDAQ:QQQ). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Most active New York Stock Exchange-traded stocks
AP - Thu Sep 04, 4:57PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Thu Sep 04, 4:57PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Merck PD-1 Inhibitor Approved For Skin Cancer
at Investor's Business Daily - Thu Sep 04, 3:33PM CDT
Merck's (MRK) pembrolizumab won FDA approval for melanoma Thursday afternoon, making it the first drug in the much-anticipated PD-1 inhibitor class to hit the U.S. market. Pembrolizumab, now branded Keytruda, was approved before the normal three...
Midday Glance: Pharmaceuticals companies
AP - Thu Sep 04, 12:16PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Market Maker Surveillance Report. PFE, GE, CSCO, VZ, MSFT, CBS, Bearishly Biased Price Friction For Tuesday, September 2nd 2014
M2 - Thu Sep 04, 9:46AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4916 companies with "abnormal" market making, 2511 companies with positive Friction Factors and 2570 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bearish bias) in their stock prices. This means that there was more buying than selling in the stocks and their stock prices dropped. Pfizer Inc (NYSE FE), General Electric Co (NYSE:GE), CISCO SYSTEMS INCORPORATED (NASDAQ:CSCO), Verizon Communications Inc (NYSE:VZ), MICROSOFT CORPORATION (NASDAQ:MSFT), Bard Ventures Ltd (NYSE:CBS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Early Glance: Pharmaceuticals companies
AP - Thu Sep 04, 9:27AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 10 a.m.:
Bristol-Myers Squibb's Eliquis Takes Aim at Johnson & Johnson
Todd Campbell, The Motley Fool - Motley Fool - Thu Sep 04, 8:41AM CDT
Bristol-Myers's Squibb and Pfizer 's Eliquis, an anticoagulant challenger to both warfarin and Johnson & Johnson 's and Bayer 's Xarelto, has seen its sales soar over the past six quarters. Eliquis, a factor Xa inhibitor used by...
Upcoming Event, Drug Approval, Technical Updates, and Research Grant - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Thermo Fisher
PR Newswire - Thu Sep 04, 8:20AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Express Scripts Holding Company (NASDAQ: ESRX) and Thermo Fisher Scientific Inc. (NYSE: TMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6210-100free.
ViiV Healthcare receives EU marketing authorisation for Triumeq(R) (dolutegravir/abacavir/lamivudine), a new once-daily single-pill regimen for the treatment of HIV
PR Newswire Europe - Wed Sep 03, 9:06AM CDT
ViiV Healthcare announced today that the European Commission (EC) has granted marketing authorisation for Triumeq((R)) (dolutegravir 50mg / abacavir 600mg / lamivudine 300mg) tablets for the treatment of HIV in adults and adolescents aged 12 years and older and weighing at least 40kg. Before initiating treatment with abacavir-containing products, screening for the presence of a genetic marker, the HLA-B*5701 allele, should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.(1) Patients who carry this genetic marker are at high risk of experiencing a hypersensitivity reaction to abacavir.
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Business Wire - Wed Sep 03, 9:00AM CDT
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Geno Germano, Group President, Global Innovative Pharma Business, at the Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2014 at 12:55 p.m. Eastern Daylight Time.
5 Things Biogen Idec Inc's Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Wed Sep 03, 8:17AM CDT
Biogen Idec held a conference call to go along with the release of second quarter earnings. Here are five things that management said on the call about Biogen Idec's ongoing prospects (quotes courtesy of S&P Capital IQ ). George Scangos...
BIND Therapeutics Appoints Two New Board Members
Business Wire - Wed Sep 03, 7:30AM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced the appointments of Eric K. Rowinsky, M.D. and Amy W. Schulman to the company's board of directors. Together the significant insights and expertise of these two industry leaders will help to guide BIND's management team in the achievement of its business and development goals.
Bristol-Myers/Pfizer's Eliquis Encourages in VTE Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:50PM CDT
Encouraging results on Bristol-Myers /Pfizer's (BMY/PFE) Eliquis was presented from an analysis of a phase III study.
Market Maker Surveillance Report. PFE, TWX, CSCO, MDT, DEPO, QQQ, Bearishly Biased Price Friction For Thursday, September 4th 2014
M2 - 2 hrs 17 mins ago
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4751 companies with "abnormal" market making, 1909 companies with positive Friction Factors and 3133 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bearish bias) in their stock prices. This means that there was more buying than selling in the stocks and their stock prices dropped. Pfizer Inc (NYSE
FE), TIME WARNER INC. (NYSE:TWX), CISCO SYSTEMS INCORPORATED (NASDAQ:CSCO), Medtronic Inc (NYSE:MDT), Depomed Inc (NASDAQ EPO), Powershares Qqq Trust Series 1 (NASDAQ:QQQ). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . Most active New York Stock Exchange-traded stocks
AP - Thu Sep 04, 4:57PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Thu Sep 04, 4:57PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Merck PD-1 Inhibitor Approved For Skin Cancer
at Investor's Business Daily - Thu Sep 04, 3:33PM CDT
Merck's (MRK) pembrolizumab won FDA approval for melanoma Thursday afternoon, making it the first drug in the much-anticipated PD-1 inhibitor class to hit the U.S. market. Pembrolizumab, now branded Keytruda, was approved before the normal three...
Midday Glance: Pharmaceuticals companies
AP - Thu Sep 04, 12:16PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Market Maker Surveillance Report. PFE, GE, CSCO, VZ, MSFT, CBS, Bearishly Biased Price Friction For Tuesday, September 2nd 2014
M2 - Thu Sep 04, 9:46AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4916 companies with "abnormal" market making, 2511 companies with positive Friction Factors and 2570 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bearish bias) in their stock prices. This means that there was more buying than selling in the stocks and their stock prices dropped. Pfizer Inc (NYSE
FE), General Electric Co (NYSE:GE), CISCO SYSTEMS INCORPORATED (NASDAQ:CSCO), Verizon Communications Inc (NYSE:VZ), MICROSOFT CORPORATION (NASDAQ:MSFT), Bard Ventures Ltd (NYSE:CBS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . Early Glance: Pharmaceuticals companies
AP - Thu Sep 04, 9:27AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 10 a.m.:
Bristol-Myers Squibb's Eliquis Takes Aim at Johnson & Johnson
Todd Campbell, The Motley Fool - Motley Fool - Thu Sep 04, 8:41AM CDT
Bristol-Myers's Squibb and Pfizer 's Eliquis, an anticoagulant challenger to both warfarin and Johnson & Johnson 's and Bayer 's Xarelto, has seen its sales soar over the past six quarters. Eliquis, a factor Xa inhibitor used by...
Upcoming Event, Drug Approval, Technical Updates, and Research Grant - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Thermo Fisher
PR Newswire - Thu Sep 04, 8:20AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Express Scripts Holding Company (NASDAQ: ESRX) and Thermo Fisher Scientific Inc. (NYSE: TMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6210-100free.
ViiV Healthcare receives EU marketing authorisation for Triumeq(R) (dolutegravir/abacavir/lamivudine), a new once-daily single-pill regimen for the treatment of HIV
PR Newswire Europe - Wed Sep 03, 9:06AM CDT
ViiV Healthcare announced today that the European Commission (EC) has granted marketing authorisation for Triumeq((R)) (dolutegravir 50mg / abacavir 600mg / lamivudine 300mg) tablets for the treatment of HIV in adults and adolescents aged 12 years and older and weighing at least 40kg. Before initiating treatment with abacavir-containing products, screening for the presence of a genetic marker, the HLA-B*5701 allele, should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.(1) Patients who carry this genetic marker are at high risk of experiencing a hypersensitivity reaction to abacavir.
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Business Wire - Wed Sep 03, 9:00AM CDT
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Geno Germano, Group President, Global Innovative Pharma Business, at the Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2014 at 12:55 p.m. Eastern Daylight Time.
5 Things Biogen Idec Inc's Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Wed Sep 03, 8:17AM CDT
Biogen Idec held a conference call to go along with the release of second quarter earnings. Here are five things that management said on the call about Biogen Idec's ongoing prospects (quotes courtesy of S&P Capital IQ ). George Scangos...
BIND Therapeutics Appoints Two New Board Members
Business Wire - Wed Sep 03, 7:30AM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced the appointments of Eric K. Rowinsky, M.D. and Amy W. Schulman to the company's board of directors. Together the significant insights and expertise of these two industry leaders will help to guide BIND's management team in the achievement of its business and development goals.
Bristol-Myers/Pfizer's Eliquis Encourages in VTE Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:50PM CDT
Encouraging results on Bristol-Myers /Pfizer's (BMY/PFE) Eliquis was presented from an analysis of a phase III study.
